SAVARA INC (SVRA) Fundamental Analysis & Valuation

NASDAQ:SVRAUS8051111016

Current stock price

5.94 USD
+0.16 (+2.77%)
At close:
5.94 USD
0 (0%)
After Hours:

This SVRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SVRA Profitability Analysis

1.1 Basic Checks

  • In the past year SVRA has reported negative net income.
  • SVRA had a negative operating cash flow in the past year.
  • In the past 5 years SVRA always reported negative net income.
  • SVRA had a negative operating cash flow in each of the past 5 years.
SVRA Yearly Net Income VS EBIT VS OCF VS FCFSVRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • SVRA's Return On Assets of -46.89% is in line compared to the rest of the industry. SVRA outperforms 48.94% of its industry peers.
  • SVRA has a Return On Equity of -58.50%. This is comparable to the rest of the industry: SVRA outperforms 57.83% of its industry peers.
Industry RankSector Rank
ROA -46.89%
ROE -58.5%
ROIC N/A
ROA(3y)-34.4%
ROA(5y)-35.67%
ROE(3y)-43.45%
ROE(5y)-47.43%
ROIC(3y)N/A
ROIC(5y)N/A
SVRA Yearly ROA, ROE, ROICSVRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • SVRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SVRA Yearly Profit, Operating, Gross MarginsSVRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

6

2. SVRA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, SVRA has more shares outstanding
  • Compared to 5 years ago, SVRA has more shares outstanding
  • The debt/assets ratio for SVRA has been reduced compared to a year ago.
SVRA Yearly Shares OutstandingSVRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
SVRA Yearly Total Debt VS Total AssetsSVRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 10.19 indicates that SVRA is not in any danger for bankruptcy at the moment.
  • SVRA has a better Altman-Z score (10.19) than 81.24% of its industry peers.
  • A Debt/Equity ratio of 0.15 indicates that SVRA is not too dependend on debt financing.
  • SVRA has a worse Debt to Equity ratio (0.15) than 64.60% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z 10.19
ROIC/WACCN/A
WACCN/A
SVRA Yearly LT Debt VS Equity VS FCFSVRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 11.85 indicates that SVRA has no problem at all paying its short term obligations.
  • SVRA's Current ratio of 11.85 is amongst the best of the industry. SVRA outperforms 84.72% of its industry peers.
  • SVRA has a Quick Ratio of 11.85. This indicates that SVRA is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 11.85, SVRA belongs to the best of the industry, outperforming 84.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.85
Quick Ratio 11.85
SVRA Yearly Current Assets VS Current LiabilitesSVRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

1

3. SVRA Growth Analysis

3.1 Past

  • The earnings per share for SVRA have decreased strongly by -12.77% in the last year.
EPS 1Y (TTM)-12.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 29.04% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y15.05%
EPS Next 2Y27.02%
EPS Next 3Y31.32%
EPS Next 5Y29.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SVRA Yearly Revenue VS EstimatesSVRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2018 2020 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
SVRA Yearly EPS VS EstimatesSVRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10 -15

1

4. SVRA Valuation Analysis

4.1 Price/Earnings Ratio

  • SVRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SVRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SVRA Price Earnings VS Forward Price EarningsSVRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SVRA Per share dataSVRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • SVRA's earnings are expected to grow with 31.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.02%
EPS Next 3Y31.32%

0

5. SVRA Dividend Analysis

5.1 Amount

  • SVRA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

SVRA Fundamentals: All Metrics, Ratios and Statistics

SAVARA INC

NASDAQ:SVRA (4/8/2026, 8:05:18 PM)

After market: 5.94 0 (0%)

5.94

+0.16 (+2.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13
Earnings (Next)05-11
Inst Owners92.57%
Inst Owner Change0%
Ins Owners2.15%
Ins Owner Change-0.46%
Market Cap1.22B
Revenue(TTM)N/A
Net Income(TTM)-118.84M
Analysts85.71
Price Target11.03 (85.69%)
Short Float %12.58%
Short Ratio13.98
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.8%
Min EPS beat(2)-8.12%
Max EPS beat(2)-3.49%
EPS beat(4)1
Avg EPS beat(4)-3.94%
Min EPS beat(4)-12.66%
Max EPS beat(4)8.5%
EPS beat(8)2
Avg EPS beat(8)-6.22%
EPS beat(12)5
Avg EPS beat(12)-4.8%
EPS beat(16)8
Avg EPS beat(16)-1.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.85%
EPS NQ rev (1m)-13.4%
EPS NQ rev (3m)-13.4%
EPS NY rev (1m)0%
EPS NY rev (3m)0.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.98
P/tB 6.35
EV/EBITDA N/A
EPS(TTM)-0.53
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0
BVpS0.99
TBVpS0.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -46.89%
ROE -58.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.4%
ROA(5y)-35.67%
ROE(3y)-43.45%
ROE(5y)-47.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.23%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.85
Quick Ratio 11.85
Altman-Z 10.19
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)145.23%
Cap/Depr(5y)348.79%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y15.05%
EPS Next 2Y27.02%
EPS Next 3Y31.32%
EPS Next 5Y29.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.72%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-73.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-74.47%
OCF growth 3YN/A
OCF growth 5YN/A

SAVARA INC / SVRA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SAVARA INC?

ChartMill assigns a fundamental rating of 2 / 10 to SVRA.


What is the valuation status for SVRA stock?

ChartMill assigns a valuation rating of 1 / 10 to SAVARA INC (SVRA). This can be considered as Overvalued.


How profitable is SAVARA INC (SVRA) stock?

SAVARA INC (SVRA) has a profitability rating of 1 / 10.


Can you provide the financial health for SVRA stock?

The financial health rating of SAVARA INC (SVRA) is 6 / 10.


What is the expected EPS growth for SAVARA INC (SVRA) stock?

The Earnings per Share (EPS) of SAVARA INC (SVRA) is expected to grow by 15.05% in the next year.